JP2008531004A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008531004A5 JP2008531004A5 JP2007556601A JP2007556601A JP2008531004A5 JP 2008531004 A5 JP2008531004 A5 JP 2008531004A5 JP 2007556601 A JP2007556601 A JP 2007556601A JP 2007556601 A JP2007556601 A JP 2007556601A JP 2008531004 A5 JP2008531004 A5 JP 2008531004A5
- Authority
- JP
- Japan
- Prior art keywords
- fra
- mice
- transgene
- bone marrow
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101150096607 Fosl2 gene Proteins 0.000 description 43
- 108700019146 Transgenes Proteins 0.000 description 28
- 241000699670 Mus sp. Species 0.000 description 22
- 210000004072 lung Anatomy 0.000 description 13
- 230000009261 transgenic effect Effects 0.000 description 12
- 210000001185 bone marrow Anatomy 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 241000699660 Mus musculus Species 0.000 description 6
- 210000002798 bone marrow cell Anatomy 0.000 description 6
- 208000005069 pulmonary fibrosis Diseases 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 238000011830 transgenic mouse model Methods 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 206010016654 Fibrosis Diseases 0.000 description 4
- 108010083644 Ribonucleases Proteins 0.000 description 4
- 102000006382 Ribonucleases Human genes 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000004761 fibrosis Effects 0.000 description 4
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 108700024394 Exon Proteins 0.000 description 3
- 108700008625 Reporter Genes Proteins 0.000 description 3
- 206010039491 Sarcoma Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 102000019034 Chemokines Human genes 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000043129 MHC class I family Human genes 0.000 description 2
- 108091054437 MHC class I family Proteins 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 231100000636 lethal dose Toxicity 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- 102000001187 Collagen Type III Human genes 0.000 description 1
- 108010069502 Collagen Type III Proteins 0.000 description 1
- 108010051219 Cre recombinase Proteins 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 101100447034 Mus musculus Fosl2 gene Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108010018242 Transcription Factor AP-1 Proteins 0.000 description 1
- 102100023118 Transcription factor JunD Human genes 0.000 description 1
- 206010057469 Vascular stenosis Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 229940096422 collagen type i Drugs 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 108060002894 fibrillar collagen Proteins 0.000 description 1
- 102000013373 fibrillar collagen Human genes 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 210000004565 granule cell Anatomy 0.000 description 1
- 230000003648 hair appearance Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 230000012976 mRNA stabilization Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 230000001936 parietal effect Effects 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical group C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- XOSXWYQMOYSSKB-LDKJGXKFSA-L water blue Chemical compound CC1=CC(/C(\C(C=C2)=CC=C2NC(C=C2)=CC=C2S([O-])(=O)=O)=C(\C=C2)/C=C/C\2=N\C(C=C2)=CC=C2S([O-])(=O)=O)=CC(S(O)(=O)=O)=C1N.[Na+].[Na+] XOSXWYQMOYSSKB-LDKJGXKFSA-L 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05003759.7 | 2005-02-22 | ||
| EP05003759A EP1692935A1 (en) | 2005-02-22 | 2005-02-22 | Transgenic animal as a model for human pulmonary disease |
| PCT/EP2006/060183 WO2006089910A1 (en) | 2005-02-22 | 2006-02-22 | Transgenic animal as a model for fibrotic diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012096064A Division JP5642729B2 (ja) | 2005-02-22 | 2012-04-03 | 線維性疾患のためのモデルとしての遺伝子導入動物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008531004A JP2008531004A (ja) | 2008-08-14 |
| JP2008531004A5 true JP2008531004A5 (https=) | 2012-06-07 |
| JP5080988B2 JP5080988B2 (ja) | 2012-11-21 |
Family
ID=34933872
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007556601A Expired - Lifetime JP5080988B2 (ja) | 2005-02-22 | 2006-02-22 | 線維性疾患のためのモデルとしての遺伝子導入動物 |
| JP2012096064A Expired - Lifetime JP5642729B2 (ja) | 2005-02-22 | 2012-04-03 | 線維性疾患のためのモデルとしての遺伝子導入動物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012096064A Expired - Lifetime JP5642729B2 (ja) | 2005-02-22 | 2012-04-03 | 線維性疾患のためのモデルとしての遺伝子導入動物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7807864B2 (https=) |
| EP (2) | EP1692935A1 (https=) |
| JP (2) | JP5080988B2 (https=) |
| CA (1) | CA2598859C (https=) |
| DK (1) | DK1855524T3 (https=) |
| ES (1) | ES2391467T3 (https=) |
| WO (1) | WO2006089910A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1482310A1 (en) * | 2003-05-30 | 2004-12-01 | Bayer HealthCare AG | Relaxin as an independent risk factor predicting mortality |
| EP1692935A1 (en) * | 2005-02-22 | 2006-08-23 | Boehringer Ingelheim International GmbH | Transgenic animal as a model for human pulmonary disease |
| ES2338971B1 (es) * | 2008-09-08 | 2011-03-11 | Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii | Modelo animal para el estudio de la angiogenesis y linfoangiogenesis in vivo. |
| US20120240246A1 (en) * | 2009-11-17 | 2012-09-20 | St. Jude Children's Research Hospital | Variant Calpastatins and Variant Calpains for Modulating the Activity or Stability of Calpain |
| KR101547283B1 (ko) | 2013-08-28 | 2015-08-25 | 한국화학연구원 | 호흡기 염증 동물모델 및 이의 용도 |
| KR101759346B1 (ko) | 2016-08-30 | 2017-07-19 | 한국화학연구원 | 폐 섬유증 동물모델 및 이의 용도 |
| CN111154802B (zh) * | 2018-11-08 | 2023-05-02 | 中国科学院分子细胞科学卓越创新中心 | Ecm1基因敲除小鼠在抗肝纤维化药物筛选中的应用 |
| CN110604098B (zh) * | 2019-09-23 | 2021-09-07 | 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） | 一种类风湿关节炎合并间质性肺病动物模型的构建方法 |
| CN113234136A (zh) * | 2020-01-23 | 2021-08-10 | 上海循曜生物科技有限公司 | 一种治疗纤维化性疾病的相关靶点及其应用 |
| EP4357458A1 (en) | 2022-10-19 | 2024-04-24 | Universitätsmedizin der Johannes Gutenberg-Universität Mainz | Inhibitors for fra-1 and fra-2 for use in the treatment of organ or tissue fibrosis |
| CN117981712B (zh) * | 2023-07-24 | 2025-02-28 | 南京鼓楼医院 | 一种腺病毒诱导肺纤维化急性加重动物模型的建立方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1140969T3 (da) * | 1998-12-14 | 2007-09-17 | Univ Miami | Bindevævsvækstfaktorfragmenter og fremgangsmåder og anvendelser deraf |
| EP1692935A1 (en) * | 2005-02-22 | 2006-08-23 | Boehringer Ingelheim International GmbH | Transgenic animal as a model for human pulmonary disease |
-
2005
- 2005-02-22 EP EP05003759A patent/EP1692935A1/en not_active Withdrawn
-
2006
- 2006-02-21 US US11/276,249 patent/US7807864B2/en not_active Expired - Lifetime
- 2006-02-22 EP EP06708450A patent/EP1855524B1/en not_active Expired - Lifetime
- 2006-02-22 DK DK06708450.9T patent/DK1855524T3/da active
- 2006-02-22 ES ES06708450T patent/ES2391467T3/es not_active Expired - Lifetime
- 2006-02-22 JP JP2007556601A patent/JP5080988B2/ja not_active Expired - Lifetime
- 2006-02-22 CA CA2598859A patent/CA2598859C/en not_active Expired - Fee Related
- 2006-02-22 WO PCT/EP2006/060183 patent/WO2006089910A1/en not_active Ceased
-
2012
- 2012-04-03 JP JP2012096064A patent/JP5642729B2/ja not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101485495B1 (ko) | 베타-마이오신 중사슬의 발현을 활성화하는 마이크로-ｒｎａ의 동정 | |
| JP4220673B2 (ja) | 遍在性クロマチンオープニングエレメント（ｕｃｏｅ）を含むポリヌクレオチド | |
| JP5642729B2 (ja) | 線維性疾患のためのモデルとしての遺伝子導入動物 | |
| CA2257148A1 (en) | Mini-adenoviral vector | |
| US6514747B2 (en) | Agouti polynucleotide compositions and methods of use | |
| JP2008531004A5 (https=) | ||
| Chen et al. | Generation of a Twist1 conditional null allele in the mouse | |
| WO2006132788A2 (en) | Transgenic models for different genes and their use for gene characterization | |
| Zhou et al. | Lineage-specific responses to reduced embryonic Pax3 expression levels | |
| JP2002511750A (ja) | ｉｎ ｖｉｖｏにおいて内皮細胞に異種ＤＮＡ配列を発現させる能力のある制御配列とその使用法 | |
| US20030192066A1 (en) | Minimal adenoviral vector | |
| Baldwin et al. | Adenovirus-mediated gene transfer during initial organogenesis in the mammalian embryo is promoter-dependent and tissue-specific | |
| Song et al. | A mouse model of inducible liver injury caused by tet-on regulated urokinase for studies of hepatocyte transplantation | |
| US7179646B2 (en) | Gene expression using T cell factor responsive element | |
| US20090165150A1 (en) | Directed complementation with removable gene of interest | |
| Cao et al. | Adenovirus mediated gene transfer to skeletal muscle | |
| JP4686598B2 (ja) | 指示された補足 | |
| JP2004517610A (ja) | 自己再編成性ｄｎａベクター | |
| García et al. | Generation of a conditional allele of the B‐myb gene | |
| US20040208846A1 (en) | Mini-Ad vector for immunization | |
| US7368553B2 (en) | Alternatively spliced nucleic acid molecules | |
| WO2002085287A2 (en) | Minimal adenoviral vectors for immunization | |
| CN118256559B (zh) | 制备射血分数保留的心衰的动物模型的方法 | |
| Jiang et al. | Skin-specifically transgenic expression of biologically active human cytoxic T-lymphocyte associated antigen4-immunoglobulin (hCTLA4Ig) in mice using lentiviral vector | |
| WO2026075201A1 (ja) | 臓器不全モデル非ヒト動物の製造方法 |